Seybold Report ISSN: 1533-9211
Priyankadevi 1, K. Revathi1*,Senthilkumari 2, Jayanthi3 1Guest faculty, JNRM College, Port Blair. 2 Assistant professor; Head of department of zoology, Chellammal College 3 Department of zoology Arignar Anna govt.arts college for women walajapet - 632 513
Vol 17, No 10 ( 2022 ) | DOI: 10.5281/zenodo.7221739 | Licensing: CC 4.0 | Pg no:1881-1899 | Published on: 18-10-2022
Abstract
The key marker apoptotic protein, B-cell lymphoma-2 (Bcl-2), is well known for its pivotal role in cancer progression through the mitochondrial intrinsic apoptotic pathway. However, till date, the exact role and mechanism of Bcl-2 in cancer progression, and their relevance to cancer therapy remains intriguing, as it acts as a double edged sword by playing a negative regulation role on apoptosis. Overexpression of Bcl-2 protein was observed in many cancer types, wherein its expression is allied with enhanced drug resistance and tumor cell survival. This characteristic feature gains attention, as inhibition of apoptosis is a hallmark of cancer. To highlight and unveil the positive and negative role of Bcl-2 in cancer therapy, various Bcl-2 inhibitors such as venetoclax, navitoclax, ABT-199, ABT-737, BCL201, etc are in current use. These inhibitors signify an exhilarating new dimension for drugs with a unique mechanism of action either as single agents or in combination with current tumor therapies. The present review would be a key pointer in envisaging the precise role of Bcl-2 inhibitors as a potential target in tumor therapy.
Keywords:
Bcl-2, apoptosis, inhibitors, carcinogenesis, anti-apoptotic.